Bayer partners with Population Health Research Institute on COVID-19 research

Bayer's Canadian arm is teaming up with the Population Health Research Institute (PHRI) to launch a new clinical research programme that strives to identify potential treatments against COVID-19.

Two clinical research studies in the programme will assess the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b.

"Treatments against COVID-19 are urgently needed as no validated options are currently available," said Mike Devoy, member of the executive committee of Bayer AG's Pharmaceuticals Division and chief medical officer.

"We want to contribute to the global fight against the coronavirus through our products and expertise and look forward to partnering with the PHRI."

An outpatient study will evaluate the combination of chloroquine with azithromycin to see if this treatment can prevent deterioration leading to hospital admission.

A second study will look at the combination of chloroquine with azithromycin, as well as interferon beta-1b, to prevent admission to intensive care, mechanical ventilation and/or death to combat COVID-19.
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.